Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095108 · ClinicalTrials.gov registry record · Phase 1
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
A Phase 1 study, sponsored by ZymoGenetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00095108 is a Phase 1 study that has completed, run by ZymoGenetics. The registered enrollment target is 43 participants.
The verdict
NCT00095108, a Phase 1 study, has completed, sponsored by ZymoGenetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.
Interventions
- DRUG Recombinant Human Interleukin-21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095108
The ClinicalTrials.gov registry entry for NCT00095108 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZymoGenetics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Human Interleukin-21 is the first listed.
NCT00095108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095108 about?
NCT00095108 is a clinical study titled "Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer". This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.
What is the current status of trial NCT00095108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2004-05. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00095108?
The interventions under investigation include: Recombinant Human Interleukin-21 (DRUG).
Who is sponsoring clinical trial NCT00095108?
This trial is sponsored by ZymoGenetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.